The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Patients With Hypertrophic Cardiomyopathy and Normal Genetic Investigations Have Few Affected Relatives
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies report hypertrophic cardiomyopathy prevalences of 5% and 12% among living relatives within three generations of probands with gene elusive hypertrophic cardiomyopathy”
From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [70]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Variants in genes that encode for myofilament proteins of the cardiac sarcomere are found in 30-50% of patients with hypertrophic cardiomyopathy.[70][71][72][73][74]”
From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [70]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Overall, the prevalence of hypertrophic cardiomyopathy in relatives of patients with gene elusive disease is less than in those with gene positive disease.”
From Current management of hypertrophic cardiomyopathy (2025) · cites this paper as [70]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Research works printed but not linked: 25
- Elliott, 2014, 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 · DOI · Paper page
- Alfares, 2015, Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity, Genet Med, 17, 880, 10.1038/gim.2014.205 · DOI · Paper page
- Burns, 2017, Multiple gene variants in hypertrophic cardiomyopathy in the era of next-generation sequencing, Circ Cardiovasc Genet, 10, 10.1161/CIRCGENETICS.116.001666 · DOI
- Harper, 2021, Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity, Nat Genet, 53, 135, 10.1038/s41588-020-00764-0 · DOI · Paper page
- Ommen, 2020, 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, J Am Coll Cardiol, 76, e159, 10.1016/j.jacc.2020.08.045 · DOI · Paper page
- Christiaans, 2011, Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy, Eur Heart J, 32, 1161, 10.1093/eurheartj/ehr092 · DOI · Paper page
- van Velzen, 2018, Outcomes of contemporary family screening in hypertrophic cardiomyopathy, Circ Genom Precis Med, 11, 10.1161/CIRCGEN.117.001896 · DOI · Paper page
- Mogensen, 2004, Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy, J Am Coll Cardiol, 44, 2315, 10.1016/j.jacc.2004.05.088 · DOI
- Ingles, 2012, A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy, Heart, 98, 625, 10.1136/heartjnl-2011-300368 · DOI
- Page, 2012, Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome, Circ Cardiovasc Genet, 5, 156, 10.1161/CIRCGENETICS.111.960831 · DOI
- Lorenzini, 2020, Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers, J Am Coll Cardiol, 76, 550, 10.1016/j.jacc.2020.06.011 · DOI
- Kampmann, 2000, Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe, Heart, 83, 667, 10.1136/heart.83.6.667 · DOI
- Haas, 2014, Atlas of the clinical genetics of human dilated cardiomyopathy, Eur Heart J, 36, 1123, 10.1093/eurheartj/ehu301 · DOI
- Hey, 2020, Clinical and genetic investigations of 109 index patients with dilated cardiomyopathy and 445 of their relatives, Circ Heart Fail, 13, 10.1161/CIRCHEARTFAILURE.119.006701 · DOI
- Risgaard, 2014, Burden of sudden cardiac death in persons aged 1 to 49 years: nationwide study in Denmark, Circ Arrhythm Electrophysiol, 7, 205, 10.1161/CIRCEP.113.001421 · DOI
- Olivotto, 2003, Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 41, 315, 10.1016/S0735-1097(02)02713-4 · DOI
- Maurizi, 2019, Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy, Circulation, 139, 830, 10.1161/CIRCULATIONAHA.118.037264 · DOI
- Hoffmann-Petersen, 2016, High prevalence of hypertension in a danish population telemedical home measurement of blood pressure in citizens aged 55-64 years in Holstebro County, Am J Hypertens, 29, 439, 10.1093/ajh/hpv116 · DOI
- Lopes, 2022, Eur Heart J Qual Care Clin Outcomes, 9, 42, 10.1093/ehjqcco/qcac006 · DOI · Paper page
- Ingles, 2017, Nonfamilial hypertrophic cardiomyopathy, Circ Cardiovasc Genet, 10, 10.1161/CIRCGENETICS.116.001620 · DOI
- Neubauer, 2019, Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry, J Am Coll Cardiol, 74, 2333, 10.1016/j.jacc.2019.08.1057 · DOI
- Zaiser, 2020, Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life, J Patient Rep Outcomes, 4, 102, 10.1186/s41687-020-00269-8 · DOI
- Ho, 2018, Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe), Circulation, 138, 1387, 10.1161/CIRCULATIONAHA.117.033200 · DOI · Paper page
- Ooi, 2020, The pitfalls of overtreatment: why more care is not necessarily beneficial, Asian Bioeth Rev, 12, 399, 10.1007/s41649-020-00145-z · DOI
- Wordsworth, 2010, DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model, Eur Heart J, 31, 926, 10.1093/eurheartj/ehq067 · DOI
Cited by
Sorted by citations
Current management of hypertrophic cardiomyopathy
Sikand, N., Stendahl, J., Sen, S., Lampert, R., & Day, S. (2025) · BMJ · doi:10.1136/bmj-2023-077274 · Cited by 26
Metadata
- Authors
- Nielsen, S. K., Hansen, F. G., Rasmussen, T. B., Fischer, T., Lassen, J. F., Madsen, T., Møller, D. S., Klausen, I. C., Brodersen, J. B., Jensen, M. S. K., & Mogensen, J.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 82
- Issue
- 18
- Pages
- 1751-1761
- ISSN
- 0735-1097
- Cited by
- 15
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
